OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a report published on Monday. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a buy rating and set a $4.25 price objective on shares of OncoCyte in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of Hold and a consensus target price of $4.06.

OncoCyte Price Performance

NASDAQ OCX opened at $3.10 on Monday. The company has a 50 day simple moving average of $3.13 and a 200-day simple moving average of $2.93. OncoCyte has a 52-week low of $2.08 and a 52-week high of $4.34.

OncoCyte (NASDAQ:OCX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. The business had revenue of $0.10 million for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%. Research analysts predict that OncoCyte will post -2.58 EPS for the current fiscal year.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.